Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka , Japan. Pituitary gonadotropin, Clinical managament
|
|
- Hollie Reynolds
- 5 years ago
- Views:
Transcription
1 Original Article Adequate Reduction Degree of Pituitary Gonadotropin Level in the Clinical Management of Short-Term Hormone Replacement Therapy of Women with Menopausal Symptoms Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka 59-, Japan Key Words Climacterium, Menopausal symptoms, Hormone replacement therapy, Pituitary gonadotropin, Clinical managament ABSTRACT The purpose of this study was to clarify the adequate reduction rate of pituitary gonadotropins in ideal clinical management of short-term hormone replacement therapy (ST-HRT) in postmenopausal women with undefined symptoms. Subjects included a total 3 postmenopausal patients between and 1 years of age who visited the Department of Obstetrics and Gynecology at Osaka Medical College Hospital for the consult of menopausal symptoms. Subjects received oral administration of conjugated equine estrogen (0.5 mg/day) and progestin (.5 mg/day) for weeks as conventional HRT. HRT was markedly effective in.7% of cases, effective in 0.7%, fairly effective in 1.9%, and ineffective in.% of cases. The plasma concentration of follicle stimulating hormone (FSH) and luteinizing hormone (LH) after administration decreased significantly (P 0.001) by 5.1% and 59.9% for markedly effective cases, and by 31.0% and 3.1% for effective cases. On the other hand, decrease in FSH and LH concentration were 1.1% and 1.3% for the fairly effective and.5% and -5.1% for ineffective cases, demonstrating a significantly greater decrease in plasma FSH and LH levels in the markedly effective and effective cases than those in ineffective cases (P 0.001). There were significant differences in the reduction rates of plasma FSH and LH levels between in cases showing (59.9% and 53.%) and not showing the adverse effects (.% and 5.9%), respectively (P ). In conclusion, efficacy of ST-HRT was significantly correlated to the degree of decrease in plasma FSH and LH levels in patients with undefined symptoms. In addition, efficacy appeared to be correlated to the incidence of side effects. The degree of reduction of FSH (.-31.0%) and LH ( %) from the baseline may possibly be used as the suitable therapeutic window for hormone levels during HRT. The present results suggest that plasma gonadotropin levels could be a useful indicator for the management of patients undergoing short-term HRT for women with menopausal symptoms. Address correspondence to: Takahisa Ushiroyama, M.D., Ph.D. Department of Obstetrics and Gynecology, Osaka Medical College, -7 Daigaku-machi, Takatsuki, Osaka 59-, Japan gyn003@poh.osaka-med.ac.jp Fax: Phone: (ext. 91)
2 9 INTRODUCTION Menopausal symptom such as hot flashes is a common and major problem for women in the years preceding and following the final spontaneous menstruation or surgical oophorectomy; referred to as the peri- and postmenopausal years (UPTON, 190; BOULET et al, 199). Such women require estrogen treatment for relief of symptoms. Timely estrogen replacement or oral contraceptive use are considered to be effective in reducing bone mineral loss (LINDSAY, 197; KLEEREKOPER et al, 1991) and for providing protection from cardiovascular disease (STAMPFER, et al, 195; STAMPER et al, 1991). Recently, the Women s Health Initiative designed the first randomized trial study for.5 years to directly address whether estrogen plus progestin had a favorable or unfavorable effects on cardiovascular heart disease (CHD) incidence and on overall risks and benefits in 1,0 predominantly healthy women (WHI Investigators, 00). They reported that the rate of women experiencing CHD events, invasive breast cancer, and venous thromboembolic disease were increased by 9%, %, and 111% for women taking estrogen plus progestin relative to placebo, respectively. The trial was stopped early based on health risks that exceeded health benefits over an average follow-up of 5. years. These results indicate that hormone replacement therapy (HRT) regimen of combined estrogen with progestin should not be initiated or continued for primary prevention of CHD. After this report, criticism against HRT intensified, and the number of clinicians who avoid the use of HRT to prevent diseases induced by estrogen deficiency has been increasing. However, since the effectiveness of HRT as a means of treating menopausal symptoms has been established and because criticism against short-term HRT has not been made, consensus is being reached on the view that HRT should be used as a means of alleviating symptoms rather than as a means of preventing diseases. While estrogen replacement improves the wellbeing and physical activity of postmenopausal women, genital bleeding during hormone replacement therapy is one of the major reasons for discontinuing treatment. Furthermore, concomitant use of progestin has been recommended to reduce the risk of endometrial hyperplasia or endometrial cancer. However, the occurrence of adverse effects due to the addition of progestin, as well as genital bleeding, remain problematic. Estrogen appears to be effective in controlling the symptoms of menopause, including hot flashes, insomnia, vaginal dryness. The present paper documents the effects of short-term hormone replacement therapy on the reduction of undefined symptoms during menopause. Changes in plasma gonadotropins were monitored throughout treatment. The correlation between the clinical effects of shortterm hormone replacement therapy and changes in plasma gonadotropins was also investigated. MATERIALS and METHODS Patients Subjects were 3 postmenopausal women treated with hormone replacement therapy with undefined symptoms were recruited from the outpatient gynecology clinic of Osaka Medical College Hospital, School of Medicine. Spontaneous menopause was determined to have occurred if there had been no menstruation in the previous 1 months. Menopausal status was also confirmed by detection of postmenopausal levels of plasma FSH, LH and estradiol concentration: an FSH of at least 30 miu/ml, LH of at least 15 miu/ml and estradiol of below 10 pg/ml. None of the patients had a history of prior use of menopausal HRT. Protocol Patients with undefined symptoms underwent hormone replacement therapy (conjugated equine estrogen (CEE) 0.5 mg and medroxyprogesterone acetate (MPA).5 mg daily, continuous administration regimen) for weeks. All subjects gave informed consent of their willingness to participate in the study. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki. Clinical evaluations were performed at the start of treatment (baseline) and after, and weeks of treatment. The intensity of the following symptoms was graded at the baseline: hot flashes, general fatigue, insomnia, depressive mood or anxiety, headache, dizziness, palpitations, muscular problems (shoulder stiffness, cramps, weakness), abdominal fullness or discomfort and physical aches. Points for intensity were assigned to each symptom: severe (3 points), moderate ( points), slight (1 point) or not present (0 point). The same evaluation was repeated after, and weeks. An improvement in symptoms was said to have occurred when the score was half the initial score. Markedly
3 adequate clinical management of hormone replacement therapy 70 effective, effective and fairly effective cases were defined as improvement within, and weeks of treatment, respectively. We also evaluated clinical symptoms with Standard Climacteric Scale by Greene (GREENE, 199). Hormonal assays Plasma FSH and LH concentrations were measured using commercially available EIA kit (Nissui Kagaku, Co. Ltd., Japan). The limit of detectability of the assay was 0. miu/ml for FSH and 0.3 miu/ml for LH. The intra- and interassay coefficients of variation were.0% and 9.%, respectively, for FSH, and 11.0% and 1.1%, respectively, for LH. Estradiol was measured using a commercially available RIA kit (Estradiol Direct Kit, Sorin Biomedica, France). The limit of detectability of the assay was 3 pg/ml, and the intra- and interassay coefficients of variation were.0% and 9.5%, respectively. The cross-reactivity of estrone in the estradiol RIA kit was less than 0.7%. Data Analysis Statistical analysis was performed using Wilcoxon-Mann-Whitney tests to evaluate differences in plasma hormone levels. P values less than 0.05 were considered significant. RESULTS Table 1 presents the clinical characteristics of the 3 postmenopausal subjects. Age, age at menopause, months since the menopause, body mass index, baseline FSH, LH and estradiol levels and baseline symptoms are summarized. The combined administration of CEE and MPA was markedly effective in.7% (93 / 3) of Table 1. Baseline characteristics of the subjects Characteristics Age (years) Age at menopause (years) Months since the menopause (months) Body mass index (kg/ ) Baseline hormone levels FSH (miu/ml) LH (miu/ml) estradiol (pg/ml) Incidence of baseline symptoms (%) (high frequent 10 symptoms in the subjects) hot flush dizziness shoulder stiffness fatigue sweating joint pain depressed mood, irritation insomnia headache physical dysphoric feeling *: involving overlap symptom Mean SD n= * Table. Assessment of the efficacy of HRT with number of days needed for improvement in ill-defined symptoms and changes of plasma gonadotropins and estradiol. Days needed for improvement in symptoms n % Plasma hormone concentration FSH (miu/ml) LH (miu/ml) Estradiol (pg/ml) Within weeks 93 / 3.7 Within weeks 13 / Within weeks 71 / No change /
4 71 cases, effective in 0.7% (13 / 3) and fairly effective in 1.9% (71 / 3). In.% ( / 3) of cases, the points score had not decreased to less than half of the initial value by weeks of treatment (Table ). The plasma concentration of FSH and LH after administration decreased significantly (P 0.001) by 5.1% (.5 1. nmiu/ml) and 59.9% (1.1. miu/ml) for markedly effective cases, and by 31.0% (7.0(1.9 miu/ml) and 3.1% (. 9. miu/ml) for effective cases. On the other hand, decreases in FSH and LH concentration were 1.1% ( miu/ml) and 1.3% ( miu/ml) for the fairly effective and.5% ( miu/ml) and 5.1% ( miu/ml) for ineffective cases, demonstrating a significantly greater decrease in plasma FSH and LH levels in the markedly effective and effective cases than those in ineffective cases (P 0.001). In mean plasma estradiol level, patients showed significantly increase in markedly effective cases (1. fold from baseline: pg/ml) and effective cases (1.1 fold from baseline: 70.. pg/ml) (P ). We also observed significantly increases in the fairly effective (9.0 fold from baseline: pg/ml) (P ) and the ineffective cases (5.1 fold from baseline: pg/ml) (P 0.001) Table 3 presents side effects of the hormone replacement therapy in the subjects. During the treatment, 17 / 3 (39.%) experienced side effects. The undesirable side effects composed of uterine bleeding (9.0%: 9 / 3), breast pain and discomfort (9.%: 31 / 3), edema (.0%: / 3), and abnormal skin feeling (5.%: 1 / 3). There were significant differences in the reduction Table 3. Side effects of hormone replacement therapy with HRT in postmenoapusal women Symptoms Uterine bleeding Breast pain, discomfort Edema Abnormal skin feeling Headache Nausea, vomiting Sense of abdominal fullness Elevation of liver transaminase Palpitations Decreased urine volume Overall incidence n % 9 / / 3 9. / / / 3 3. / 3.5 / / 3 0. / / / Table. Comparison of changes in plasma FSH, LH and estradiol levels during weeks of treatment with HRT between women who did and did not experience side effects Treatment weeks Reduction or elevation rate from initial levels with side effects without side effects n=17 n=197 Statistical difference FSH LH Estradiol % % 5..% % % % % % 5.1. fold fold 9.5. fold 1.7. fold % % %. 0.% 9..3% % % %. 1.1 fold fold. 5. fold fold
5 adequate clinical management of hormone replacement therapy 7 degree of plasma FSH and LH levels in the weeks treatment with HRT between in cases experienced ( % and %) and not experienced side effects (. 0.% and %), respectively (P 0.001) (Table ). The mean plasma FSH, LH and estradiol levels were analyzed in relation to the type of side effects (uterine bleeding, edema, breast pain or discomfort, and abnormal skin feeling) occurring during weeks after the start of treatment (Table 5). At week-, the mean plasma FSH level decreased to.9 5. miu/ml for patients who developed uterine bleeding (n = 9) and miu/ml for patients who developed edema (n = ), which was 3.% and 3.1% of the pretreatment level, respectively. The mean plasma LH level at treatment week- decreased to miu/ml for patients who developed uterine bleeding and miu/ml for patients who developed edema, which was 1.7% and.3% of the pre-treatment level, respectively. The mean FSH levels for these two groups was significantly lower than that for patients who developed abnormal skin feeling (3. 1.5mIU/ml, n = 1) (P 0.05). The plasma estradiol level for patients who developed uterine bleeding (. 0. pg/ml) was significantly higher than that for patients who developed abnormal skin feeling ( pg/ml) (P 0.05). There were significant differences in the reduction degree of plasma FSH and LH levels in the weeks treatment with HRT between in cases experienced ( % and %) and not experienced uterine bleeding ( % and 3.0.%), respectively (P 0.001) (Table ). Of the 9 patients who developed uterine bleeding, 7 (7.%) showed a reduction in both plasma FSH and LH levels to the levels equivalent to those seen in individuals during sexual maturation. Table 5. Comparison of plasma FSH, LH and estradiol levels during weeks of treatment with HRT in women who experienced different side effects Side effects n FSH (miu/ml) LH (miu/ml) Estradiol (pg/ml) Uterine bleeding Edema Breast pain, discomfort Abnormal skin feeling *: P * * * Table. Comparison of changes in plasma FSH, LH and estradiol levels during weeks of treatment with HRT between women who did and did not experience uterine bleeding Treatment weeks Reduction or elevation rate from initial levels with uterine bleeding without uterine bleeding n=9 n=30 Statistical difference FSH LH Estradiol % % 57..% % % %. 9.5% % 7.3. fold fold fold fold % % % % 1.1.3% % % 3.0.% fold fold.1 5. fold. 5.5 fold
6 73 DISCUSSION Undefined symptoms such as hot flashes are among the primary reasons for women who are approaching the menopausal and postmenopausal years to seek medical attention. Since the efficacy of a continuous estrogen ( mg conjugated equine estrogen) -progestin (.5 mg medroxyprogesterone acetate) regimen has been recommended as the primary HRT for postmenopausal patients (WEINSTEIN, 197), this regimen has been used as the standard method of HRT for the past decade. However, a concern for both physicians and patients is that higher doses of estrogen could precipitate additional estrogenrelated side effects and increase the risk of and breast cancer. The publication of two large randomized clinical trials the Heart and Estrogen / progestin Replacement Study (HERS) and the Women s Health Initiative (WHI) of continuous-combined estrogen-progestin therapy (HRT) for postmenopausal women (WHI INVESTIGATORS, 00; HULLY et al, 199) have been reported as providing new and shocking information on HRT. These two major studies have put postmenopausal hormone replacement therapy as preventive strategy into a new perspective. Especially, in the wake of the publication of WHI results (WHI INVESTIGATORS, 00), numerous comments and position statements were issued, most of which endorsed the conclusions of the WHI researchers: in essence, this would limit the prescribing of hormone therapy to symptomatic menopausal women, for a period of -5 years (NOTELOVITZ, 003). A questionnaire survey, conducted of 1 middle-aged and elderly women in Japan months after WHI-HRT publication, yielded the following findings (USHIROYAMA et al, 003). It was shown that HRT was understood as a treatment of menopausal disorders at the highest rate (31.%) among HRT non-users, but was also understood as a treatment of osteoporosis (17.5%) and a treatment for prevention of dementia (1.%). Only.% of the respondents answered that HRT is a means of primary prevention of CHD. In view of the level of awareness of Japanese women about HRT, we may say that also in Japan, like in many other countries in the world, HRT should not be administered as a means of preventing osteoporosis and CHD but its use should be confined to short-term treatment of symptomatic menopausal women. Under such circumstances, we performed short-term HRT in postmenopausal women complaining of menopausal symptoms to achieve ideal outpatient management in terms of efficacy and side effects, using plasma gonadotropin and estradiol levels as indicators. Recently, we demonstrated that estriol was shown to be effective in approximately 7%, 7%, 5%, and 0% of women who complained of hot flashes, general fatigue, palpitations, and muscular problems, respectively, in postmenopausal period (USHIROYAMA et al, 001), and the significant relationship between efficacy and the reduction degree of gonadotropins, whereas the estradiol level remained 5 pg/ml despite receiving estriol mg daily. We supposed that the reduction degree of FSH ( %) and LH (.0-.3%) could be used as the suitable therapeutic window for hormone levels during estrogen replacement with estriol for undefined symptoms in postmenopausal women. In this study we observed that significantly greater decrease in plasma FSH and LH levels, and increase in plasma estradiol level in the markedly effective and effective cases than those in ineffective cases. Furthermore, significant differences in the reduction degree of plasma FSH and LH levels between in cases experienced and not experienced side effects. Adverse effects occurred in 39.% (17 / 3) of all cases. The major adverse effects were uterine bleeding (9.0%) and breast pain (9.%). During the past decade, a number of different estrogens and progestins at different doses have been tested in order to find the ideal combination. In spite of various dose combinations being tested, most investigators have reported a relatively high incidence of uterine bleeding (0-57% of patients) during the 3- months of treatment (MATTSSON et al, 19; WEINSTEIN et al, 1990; HARGROVE et al, 199). Uterine bleeding, breast pain and discomfort are very uncomfortable for patients. Plasma FSH and LH levels decreased more greatly in patients who developed uterine bleeding or edema. Percent increase in plasma estradiol level was also greater in patients who developed uterine bleeding. To reduce the dropout rate and enhance compliance, these adverse effects should be suppressed as much as possible. Recently, the concept of physiological HRT with transdermal estrogen preparations has been introduced for long-term HRT to deal with postmenopausal estrogen deficiency. DUPONT et al. reported that the plasma estradiol level was approximately 0-00 pg/ml and the E1/E ratio was 5-7 after conjugated equine estrogen therapy alone, but
7 adequate clinical management of hormone replacement therapy 7 that the E1/E ratio was approximately 1 after transdermal estrogen therapy. Based on these results, DUPONT et al. (1990) concluded that the E1/E ratio close to the physiological E1/E ratio seen before menopause could be achieved by transdermal estrogen therapy. Concerning the uterine bleeding, a side effect, it is known that an increase in the percentage of progestin contained in HRT preparations elevates the incidence of endometrial atrophy. High doses of progestin can also adversely affect the metabolism of serum lipoprotein. Therefore, adjustment of the dose level for individual patients is essential (DARJ et al, 1991; SIDDLE et al, 191; OTTOSSON et al, 195). Plasma gonadotropin level will serve as a valuable indicator when making such adjustment. Thus, the plasma concentration of FSH and LH may be important in the management of HRT. According to present results, it is observed that higher reduction of plasma FSH and LH levels by the HRT induce not only higher clinical efficacy but higher incidence of side effects. The degree of reduction of FSH (.-31.0%) and LH ( %) from the baseline may possibly be used as the suitable therapeutic window for hormone levels during HRT. Though HRT is expected to exert high efficacy in the actual clinical practice, it is desirable to avoid a high incidence of adverse effects as far as possible. In cases where the therapy was rated as showing reliable efficacy although the response was not rated as complete responses, the mean percent reduction in FSH and LH was 31.0% and 3.1%, respectively. If the percent reduction in FSH and LH becomes higher than these levels, the number of cases showing CR will increase, but adverse effects will be more likely to appear. Inversely, if the percent reduction in FSH and LH is lower than these levels, the efficacy will be lower, but side effects are less likely. Because the mean reduction in FSH and LH was.% and 5.9% in cases free of side effects, we may say that if the goal of the amount of reduction is set at.-31.0% for FSH and % for LH, reliable clinical efficacy with minimal side effects is expected although CR is unlikely to be achieved. It is proper that clinical managements tailored to individual case are needed, but setting these clinical indicator will be contribute as a therapeutic window of pituitary gonadotropin level. Uterine bleeding is one of the most significant adverse effects of HRT. In patients showing uterine bleeding, the plasma FSH level decreased to about half after weeks of HRT, and the percent reduction in FSH after only weeks of HRT was about 0% greater than that in patients free of uterine bleeding (P 0.001). We therefore considered that a large reduction in FSH in early stages of HRT could elevate the incidence of uterine bleeding as an adverse reaction. If the plasma FSH level has decreased by 0-50% during the first weeks of HRT, it is considered that sufficient management and care are needed in continuing the therapy. A similar trend was also noted in the change in plasma LH level, but the difference between patients showing and free of uterine bleeding was smaller for plasma LH level than for plasma FSH level. After weeks of HRT, percent reduction in plasma FSH and LH level was 3.% and 5.1% respectively, in cases showing uterine bleeding as an adverse reaction. To minimize the onset of uterine bleeding as an adverse reaction to HRT, it is advisable to keep percent reduction in plasma FSH and LH levels smaller than the mean percent reduction seen in patients free of uterine bleeding (reduction by % for FSH and 3.0.% for LH). In other words, we may say that the incidence of uterine bleeding as an adverse reaction to HRT becomes higher if percent reduction in FSH or LH level exceeds the mean percent reduction. If the percent reduction is kept below the mean - 1SD (5.1% for FSH and 35.3% for LH), the incidence of uterine bleeding will be considerably low. Therefore, taken together, the present results suggest that a reduction of approximately less than 0% and 35% from initial FSH and LH levels, respectively, may be the optimal value for a suppression of uterine bleeding during HRT. Percent increase in plasma estradiol level may also be adopted as a therapeutic window, but the SD of this parameter in our data was too large to allow us setting a reliable indicator of percent increase in plasma estradiol level. We may say that time has come to review the indications of HRT when dealing with estrogen deficiency-induced conditions during the postmenopausal period. Under such circumstances, it is necessary to establish further strategies for short-term treatment of symptomatic menopausal women. The results obtained in the present study suggest that patient management based on periodical measurement of blood hormone levels is essential to elevate drug compliance with the goals of maximizing the clinical efficacy of HRT and minimizing side effects to this therapy.
8 75 References BOULET MJ, ODDENS BJ, LEHERT P: Climacteric and menopause in seven south-east Asian countries. Maturitas 19: , 199 DARJ E, NILSSON S, AXELSSON O, HELLBERG D: Clinical and endometrial effects of oestradiol and progesterone in postmenopausal women. Maturitas 13: , 1991 DUPON A: Efficacy of percutaneous estradiol and oral estrogens as replacement therapy in postmenopausal women. In: Physiological hormone replacement therapy, Ed. By Dusitsin N.and Notervitz M, P37, The Parthenon Publishing Group, New Jersey, 1990 GREENE JG.: Constructing a standard climacteric scale. Maturitas 9: 5-31, 199 HARGROVE J, MAXON W, WENTZ J: Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 73: 0-1, 199 HULLY S, GRADY D, BUSH T. FOR THE HEART AND ESTROGEN PROGESTIN REPLACEMENT STUDY (HERS) RESEARCH GROUP: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopusal women. JAMA 0: 05-13, 199 KLEEREKOPER M, BRIENZA RS, SCHULTZ LR: Oral contraceptive use may protect against low bone mass. Arch Intern Med 151: , 1991 LINDSAY R: Prevention of postmenopausal osteoporosis. Obstet Gynecol Clin N Am 1: 3-7, 197 MATTSSON LA, CULLBERG G, SAMSIOE G.: Evaluation of continuous combined oestrogen / progestogen regimen for climacteric complaints. Maturitas : 95-10, 19 NOTELOVITZ M: The clinical practice impact of the Women s HealthInitiative: political vs biologic correctness. Maturitas : 3-9, 003 OTTOSSON UB, JOHANSSON BG, von SCHOULTZ B: Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: A comparison between progestogens and natural progesterone. Am J Obstet Gynecol 151: 7-751, 195 SIDDLE NC, TOWNSEND PT, YOUNG O, MINARDI J, KING RJ, WHITEHEAD MI: Dose dependent effects of synthetic progestins on the biochemistry of the estrogenized postmenopausal endometrium. Acta Obstet Gynecol Scand 1 (Suppl): 17-, 191 STAMPFER MJ, WILLETT WC, COLDITZ GA: A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Eng J Med313: , 195 STAMPFER MJ, COLDITZ GA, WILLETT WC: Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow up from the nurses' health study. N Eng J Med 35: 75-7, 1991 UPTON GV. The physiology of the perimenopausal years: a minireview: Int J Gynecol Obstet 17: , 190 USHIROYAMA T, SAKAI M, HIGASHIYAMA T, IKEDA A, UEKI M: Estrogen replacement therapy in postmenopausal women: a study of the efficacy of estriol and changes in plasma gonadotropin levels. Gynecol Endocrinol 15: 7-0, 001 USHIROYAMA T, SHINTANI M, HONJO H, A STUDY GROUP FOR FUTURE HRT: A study of cognition of middle-aged Japanese women for Hormone replacement therapy by questionnaires - influence of WHI's report in JAMA-. Adv Obstet Gynecol 55: 1-30, 003 (in Japanese) WEINSTEIN L: Efficacy of a continuous estrogenprogestin regimen in the menopausal patient. Obstet Gynecol 9: 99-93, 197 WEINSTEIN L, BEWTRA C, GALLAGHER J: Evaluation of continuous combined low-dose regimen of oestrogen-progestin for treatment of the menopausal patient. Am J Obstet Gynecol 15: , 1990 WOMEN S HEALTH INITIATIVE INVESTIGATORS: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA : , 00 Received May 9, 005 Accepted July 1, 005
Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Predicting the menopause The menopause marks the end of ovarian follicular activity and is said to have occurred after 12 months amenorrhoea. The average age of the menopause is between 45 and 60 years
More informationMENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
More informationWomen s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
More informationHormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare
Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest
More informationMenopause management NICE Implementation
Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not
More informationAppendix: Reference Table of HT Brand Names
Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug
More information25 mg oestradiol implants--the dosage of first choice for subcutaneous oestrogen replacement therapy?
Research Subcutaneous estrogen replacement therapy. Jones SC. Journal of Reproductive Medicine March, 2004; 49(3):139-142. Department of Obstetrics and Gynecology, Keesler Medical Center, Keesler Air Force
More information5. Summary of Data Reported and Evaluation
326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal
More informationMenopause & HRT. Matt McKenna Elliot Davis
Menopause & HRT Matt McKenna Elliot Davis Menopause Before age 40: Premature Menopause After 12 months clinical diagnosis made Depletion of Ovarian Follicles Oestrogen Progesterone LH FSH Spontaneous Amemorrhoea
More informationMenopause and HRT. John Smiddy and Alistair Ledsam
Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationPost-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018
Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationVirtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,
More informationPERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
More informationManagement of Menopausal Symptoms
Management of Menopausal Symptoms Tammie Koehler DO, FACOG 1 Menopause Permanent cessation of menstruation that occurs after the loss of ovarian activity Determined to have occurred after 1 full year of
More informationAusPharm CE Hormone therapy 23/09/10. Hormone therapy
Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of
More informationMenopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition
Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists
More informationA Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis
SH SUEN & SCS CHAN A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis Sik Hung SUEN MBChB, MRCOG Resident
More informationOBSTETRICS & GYNECOLOGY
AUGUST 2011 NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: BHRT for Menopause
More informationOB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc.
OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. Napa, California IMPORTANT SAFETY INFORMATION ABOUT EVAMIST: WARNING: ENDOMETRIAL CANCER,
More information2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK
2017 Position Statement of Hormone Therapy of NAMS: overview SHELAGH LARSON, MS, RNC WHNP, NCMP ACCLAIM, JPS HEALTH NETWORK WHI the only large, long-term RCT of HT in women aged 50 to 79 years, Drug trail
More informationHRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College
HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now
More informationMenopause: diagnosis and management NICE guideline NG23. Published November 2015
Menopause: diagnosis and management NICE guideline NG23 Published November 2015 1 Full title: Menopause : diagnosis and management Available at: http://www.nice.org.uk/guidance/ng23 Guideline published
More informationWEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital
WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased
More informationA Practitioner s Toolkit for the Management of the Menopause
Medicine, Nursing and Health Sciences A Practitioner s Toolkit for the Management of the Menopause Developed by the Women s Health Research Program School of Public Health and Preventive Medicine Monash
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG Consultant Gynaecologist Heart of England NHS Foundation Trust rajsaha1@yahoo.co.uk Content of today s talk Aims
More informationPractical recommendations for hormone replacement therapy in the peri- and postmenopause
CLIMACTERIC 2004;7:in press Practical recommendations for hormone replacement therapy in the peri- and postmenopause Recommendations from an Expert Workshop, February 2004 Henry Burger, Australia; David
More informationEstrogen and progestogen therapy in postmenopausal women
Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone
More informationManagement of Perimenopausal symptoms
Management of Perimenopausal symptoms Serge Rozenberg CHU St Pierre Université libre de Bruxelles Belgium serge_rozenberg@stpierre-bru.be serge.rozenberg@skynet.be Conflict of interest & Disclosure Conflicts
More informationHKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 revised January 2003
HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 revised January 2003 published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College
More informationMenopause & HRT. Rosie & Alex. Image:
Menopause & HRT Rosie & Alex Image: http://www.keepcalm-o-matic.co.uk/ Menopause The permanent cessation of menstruation for 12 months When does it happen? Average age 51 Image: Nature Medicine - 12, 612-613
More informationHormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG PG Cert. Advanced Gynaecology Endoscopy Consultant Gynaecologist Heart of England NHS Foundation Trust Spire Parkway
More informationHormonal Control of Human Reproduction
Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with
More informationBefore you prescribe
Initiating hormone replacement therapy (HRT) / menopausal hormone therapy (MHT) Dr Sonia Davison Jean Hailes Consultant Endocrinologist Before you prescribe Ensure there are no contraindications to HRT/MHT
More informationTraditional Chinese Medicine (TCM) in the Management of Menopausal Symptoms/Conditions
Introduction www.womenshealthclinic.co.uk Traditional Chinese Medicine (TCM) in the Management of Menopausal Symptoms/Conditions XY Zhang, PhD MD Women s Health Clinic, London, UK Email: xzhang@womenshealthclinic.co.uk
More informationHKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 Revised November BENEFITS OF HRT
HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 Revised November 2006 Published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College
More information4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms
550 4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms 4.1 Absorption, distribution, metabolism and excretion 4.1.1 Humans The pharmacokinetics of the newer progestogens, desogestrel,
More informationDrug Class Review on Estrogen for Treatment of Menopausal Symptoms and Prevention of Low Bone Density & Fractures. Final Report
Drug Class Review on Estrogen for Treatment of Menopausal Symptoms and Prevention of Low Bone Density & Fractures Final Report Heidi D. Nelson, MD, MPH Peggy Nygren, MA Benjamin K. S. Chan, MS Produced
More informationBioidentical Hormones: Just the Facts
Bioidentical Hormones: Just the Facts Melissa McNeil, MD, MPH Professor of Medicine and Obstetrics, Gynecology and Reproductive Sciences Chief, Section of Women s Health University of Pittsburgh Disclosures!
More informationHORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer
HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy
More informationHOW TO MAKE SENSE OF MENOPAUSE. by Steven. F. Hotze, M.D.
HOW TO MAKE SENSE OF MENOPAUSE by Steven. F. Hotze, M.D. INTRODUCTION Dr. Hotze is founder of Hotze Health & Wellness Center and author of the book Hormones, Health, and Happiness. He has enabled thousands
More informationpresents with Ken Sekine, MD
presents Pioneering Technologies For Pellet Hormone Therapy Lifestyle Based Medicine A Primer for Clinicians with Ken Sekine, MD Dr. Sekine is a board certified OB-GYN who has been in private practice
More informationIs Extract ERr731 from the Rheum Rhaponticum Effective in Relieving Menopausal Symptoms in Women Aged 45 to 55 Years of Age?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Extract ERr731 from the Rheum Rhaponticum
More informationPostmenopausal hormone therapy - cardiac disease risks and benefits
Postmenopausal hormone therapy - cardiac disease risks and benefits Tomi S. Mikkola, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Helsinki, Finland Disclosures Speaker/consulting
More informationFemale Sexual Hormones Indications and Therapy
Female Sexual Hormones Indications and Therapy In puberty, a woman has about 400,000 ovules, at the age of 40-44 years about 17,000 only. On average, each grown-up woman (still having ovulation) loses
More informationHysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure
The Journal of International Medical Research 2007; 35: 416 421 Hysterectomy with Preservation of both Ovaries does not Result in Premature Ovarian Failure V ATAY 1, T CEYHAN 2, İ BASER 2, S GUNGOR 2,
More information22/09/2014. Menopause Management. Menopause. Menopause symptoms
Menopause Management Dr Sonia Davison Jean Hailes for Women s Health Menopause Time of last menstrual period - average age 51 Premature Menopause: occurs before age 40 Perimenopause (menopause transition):
More informationOBSTETRICS & GYNECOLOGY
JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Female Sexual Arousal
More informationHormone therapy for menopausal vasomotor symptoms
Hormone therapy for menopausal vasomotor symptoms Given our available (better) options for treating hot flashes, can we reduce our use of medroxyprogesterone acetate? OBG Manag. 2014;26(7):10,13 15. Robert
More informationEstrogens and progestogens
Estrogens and progestogens Estradiol and Progesterone hormones produced by the gonads are necessary for: conception embryonic maturation development of primary and secondary sexual characteristics at puberty.
More informationLow & Ultra Low Dose HRT The Cardiovascular Impact
Low & Ultra Low Dose HRT The Cardiovascular Impact Wyeth Symposium, Turin 29 th Sept 2007 Nick Panay Consultant Gynaecologist Queen Charlotte s & Chelsea and Chelsea & Westminster Hospitals Honorary Senior
More informationHRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD
Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology
More informationSerum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women
Maturitas 50 (2005) 19 29 Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women Toshiyuki Yasui a,, Hirokazu Uemura a, Yuka Umino
More informationPrior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD
Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD JoAnn V. Pinkerton, MD Professor of Obstetrics and Gynecology Director,
More informationBalancing Hormone Function in Women By Meghna Thacker, NMD
Balancing Hormone Function in Women By Meghna Thacker, NMD Hormone function is central to health and well being in both men as well as women. A problem encountered with any one endocrine gland can lead
More informationSex, hormones and the heart
Sex, hormones and the heart Dr Louise Newson BSc(Hons) MBChB(Hons) MRCP FRCGP www.menopausedoctor.co.uk #IandA2017 Declaration I have had financial relationships (lecturer, writer, member of advisory boards
More informationNEW SELECTIVE TISSUE ESTROGENIC ACTIVITY REGULATOR (STEAR) IN MENOPAUSAL THERAPY IN TAIWAN
ORIGINAL ARTICLE Tibolone Compliance and Efficacy in Women Living in Taiwan NEW SELECTIVE TISSUE ESTROGENIC ACTIVITY REGULATOR (STEAR) IN MENOPAUSAL THERAPY IN TAIWAN Kuan-Chong Chao*, Peng-Hui Wang, Ming-Shyen
More informationYear: Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy
Year: 2013 - Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy By: Dr David W Sturdee, Immediate past President International Menopause Society and Hon Consultant Gynaecologist, Solihull
More informationPresentation to the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Therapy
Presentation to the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Therapy March 5, 2019 Nese Yuksel, BScPharm, PharmD, FCSHP, NCMP Professor Faculty of Pharmacy and Pharmaceutical
More informationHORMONES AND YOUR HEALTH Charlie Tucker Pharm. D
HORMONES AND YOUR HEALTH Charlie Tucker Pharm. D All of the hormones in your body are designed to work together. This is God s plan. Therefore, if one is altered, or deficient, it will affect the actions
More informationWestern Locality Shared care information ~ Gonadorelin Analogues (Gnrh)
Western Locality Shared care information ~ Gonadorelin Analogues (Gnrh) Specialist: Please complete the Shared Care letter sending a request to GP (see bottom of the page) April 2013 GP: Please indicate
More informationPremature Menopause : Diagnosis and Management
Guideline Number 3 : August 2010 Premature Menopause : Diagnosis and Management Introduction : Premature menopause is a serious condition that affects young women and remains an enigma. The challenges
More informationCASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology
CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology A 49-year-old woman complains of irregular menses over the past 6 months, feelings of inadequacy, vaginal dryness, difficulty sleeping, and episodes
More informationWhat s New in Menopause Management. Objectives
What s New in Menopause Management Leslee L. Subak, MD Professor of Obstetrics, Gynecology & Reproductive Science University of California, San Francisco Objectives Define the menopause transition Review
More informationResearch Article The Treatment with Hormone Replacement Therapy and Phytoestrogens and The Evolution of Urogenital Symptoms in Postmenopausal Women
Cronicon OPEN ACCESS PHARMACEUTICAL SCIENCE Research Article The Treatment with Hormone Replacement Therapy and Phytoestrogens and The Evolution of Urogenital Symptoms Bungau S 1, Tit DM 1 *, Fodor K 1
More informationOriginal Policy Date
MP 5.01.30 Implantable Hormone Pellets Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy created with literature search/12:2013 Return
More informationEstrogen (conjugated estrogens & ethinyl estradiol) Addition to the List
Estrogen (conjugated estrogens & ethinyl estradiol) Addition to the List Note: Commonly prescribed medication. Literature question Is estrogen effective and safe? Are conjugated estrogens effective and
More informationThe Practice Committee of the American Society for Reproductive Medicine,
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. PRACTICE COMMITTEE Estrogen
More informationOVERVIEW OF MENOPAUSE
OVERVIEW OF MENOPAUSE Nicole Budrys, MD, MPH Reproductive Endocrinology Michigan Center for Fertility and Women s Health Presented at SEMCME March 13,2019 Objectives Define menopause Etiology of menopause
More informationCLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN
CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN Nanette K. Wenger, MD, is a recognized authority on women and coronary heart disease. She chaired the US National Heart, Lung, and Blood Institute conference
More informationEndocrine Steroids 2. Signal transduction 3. Prostaglandins
Endocrine - 2 1. Steroids 2. Signal transduction 3. Prostaglandins Estrogen Menopause (pause in the menes) ["change of life" at about 50] - lack of estrogen. (Some hysterectomy or ovarian cancer surgeries
More informationOrilissa (elagolix) NEW PRODUCT SLIDESHOW
Orilissa (elagolix) NEW PRODUCT SLIDESHOW Introduction Brand name: Orilissa Generic name: Elagolix Pharmacological class: GnRH antagonist Strength and Formulation: 150mg, 200mg; tabs Manufacturer: AbbVie
More informationPrevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes*
FERTILITY AND STERILITY Vol. 59, No.5, May 1993 Copyright e 1993 The American Fertility Society Printed on acid-free paper in U.S.A. Prevention of endometrial hyperplasia by progesterone during long-term
More informationImvexxy (estradiol) NEW PRODUCT SLIDESHOW
Imvexxy (estradiol) NEW PRODUCT SLIDESHOW Introduction Brand name: Imvexxy Generic name: Estradiol Pharmacological class: Estrogen Strength and Formulation: 4mcg, 10mcg; vaginal inserts Manufacturer: TherapeuticsMD,
More informationHormone Restoration and Support
Hormone Restoration and Support As a doctor with a strong interest in functional medicine, I strive to help my patients to achieve optimal health in the best ways I know how. This encompasses a combined,
More informationDifference between vagifem and yuvafem
Difference between vagifem and yuvafem Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer. Estrogen-alone
More informationLessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice
Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and
More informationEfficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy in Korean postmenopausal women
Short Communication Obstet Gynecol Sci 2017;60(2):213-217 https://doi.org/10.5468/ogs.2017.60.2.213 pissn 2287-8572 eissn 2287-8580 Efficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationWHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro
WHI, HERS y otros estudios: Su significado en la clinica diária III Congreso Ecuatoriano de Climaterio Menopausia y Osteoporosis por Manuel Neves-e-Castro (Lisboa-Portugal) Julho, 2003 Machala The published
More informationCLIMARA 25 CLIMARA 50 CLIMARA 75 CLIMARA 100
REGISTERED PACKAGE INSERT SCHEDULING STATUS S4 PROPRIETARY NAMES AND DOSAGE FORMS CLIMARA 25 CLIMARA 50 CLIMARA 75 CLIMARA 100 Estradiol transdermal systems COMPOSITION Climara 25: Climara 50: Climara
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationEffects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms
Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Photo (compulsory) Steven R Goldstein, MD 1 ; Ginger D Constantine, MD 2 ; David F Archer, MD 3 ; James H Pickar,
More informationHORMONE REPLACEMENT THERAPY-UPDATE KHALED SAKHEL, MD FACOG FACS FAIUM ASSOCIATE PROFESSOR EASTERN VIRGINIA MEDICAL SCHOOL
HORMONE REPLACEMENT THERAPY-UPDATE KHALED SAKHEL, MD FACOG FACS FAIUM ASSOCIATE PROFESSOR EASTERN VIRGINIA MEDICAL SCHOOL INTRODUCTION NORMAL WOMEN HAVE MENOPAUSE AT A MEAN AGE OF 51 YEARS, WITH 95 PERCENT
More informationNavigating the Change: Leading Patients Through Menopause
4:30pm - 5:30pm: Breakout 5 - Women s Health Option A: Navigating the Change: Leading Patients Through Menopause ACPE UAN 0107-0000-10-025-L01-P 0.1 CEU/1.0 Hr. Activity Type: Application-Based Program
More informationTopics. Periods Menopause & HRT Contraception Vulva problems
Girls stuff Topics Periods Menopause & HRT Contraception Vulva problems Menorrhagia Excessive menstrual loss occurring with regular or irregular cycles Ovulatory Anovulatory Usual blood loss 30-40ml per
More informationLET S START WITH (AND REMEMBER WE ARE TALKING ABOUT LOCAL E2) THERAPUTIC AGENTS: ARE THEY SAFE? Systemic HT/ET. Ospemifene. Local Estrogen Therapy
THERAPUTIC AGENTS: ARE THEY SAFE? Steven R. Goldstein, M.D. Professor of Obstetrics & Gynecology New York University School of Medicine Director of Gynecologic Ultrasound Co-Director of Bone Densitometry
More informationMenopausal Management: What Has Changed?
Menopausal Management: What Has Changed? Julia V. Johnson, M.D. Professor and Chair, OB/GYN University of Massachusetts Medical School UMass Memorial Medical Center Conflicts of Interest None Learning
More informationEffects of Hormone Therapy on Serum Lipid Levels in Postmenopausal Korean Women
J MM pissn: 2288-6478, eissn: 2288-6761 Journal of Menopausal Medicine 2015;21:104-111 Original Article Effects of Hormone Therapy on Serum Lipid Levels in Postmenopausal Korean Women Jee-Yeon Lee, Hye
More informationAbnormal Uterine Bleeding Case Studies
Case Study 1 Abnormal Uterine Bleeding Case Studies Abigail, a 24 year old female, presents to your office complaining that her menstrual cycles have become a problem. They are now lasting 6 7 days instead
More informationJames H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
Disclosure Estrogen Therapy After Postmenopausal Hysterectomy: Issues, Challenges, Risks/Benefits James H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
More informationNICE guideline Published: 12 November 2015 nice.org.uk/guidance/ng23
Menopause: diagnosis and management NICE guideline Published: 12 November 2015 nice.org.uk/guidance/ng23 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationPostmenopausal hormones and coronary artery disease: potential benefits and risks
CLIMACTERIC 2007;10(Suppl 2):21 26 Postmenopausal hormones and coronary artery disease: potential benefits and risks R. A. Department of Obstetrics and Gynecology, Columbia University, New York, New York,
More informationREVIEW POSSIBLE DELETION OF MEDROXYPROGESTERONE FROM THE 14 TH WHO MODEL LIST OF ESSENTIAL MEDICINES
REVIEW POSSIBLE DELETION OF MEDROXYPROGESTERONE FROM THE 14 TH WHO MODEL LIST OF ESSENTIAL MEDICINES Author: Lenita Wannmacher Application: To perform a quick review of medroxyprogesterone acetate tablet
More informationMenopause. Medicines To Help You
Medicines To Help You Menopause Use this guide to help you talk to your doctor, pharmacist, or nurse about your hormone medicines. The guide lists all of the FDA-approved products now available to treat
More information06-Mar-17. Premature menopause. Menopause. Premature menopause. Menstrual cycle oestradiol. Premature menopause. Prevalence ~1% Higher incidence:
Menopause Dr Sonia Davison MBBS FRACP PhD Endocrinologist and Clinical Fellow, Jean Hailes for Women s Health Women s Health Research Program, Monash University = the last natural menstrual period depletion
More information